Introduction
============

All healthy nontraveling Muslims are required to abstain from taking any food or beverages between dawn and sunset (fasting) for one complete lunar month every year (ie, the month of Ramadan).[@b1-ppa-10-1709] Diabetes is one of the key diseases that need careful observation during Ramadan.[@b2-ppa-10-1709] Patients with diabetes may face possible major metabolic complications during fasting, including hypoglycemia, hyperglycemia with or without the risk of impending ketosis, dehydration, and thrombosis.[@b3-ppa-10-1709]--[@b5-ppa-10-1709] Saudi Arabia has one of the highest diabetes prevalence in the world.[@b6-ppa-10-1709],[@b7-ppa-10-1709] Additionally, more than half of the top ten countries with the highest diabetes prevalence worldwide have a majority of Muslim population.[@b7-ppa-10-1709] Since fasting is regarded by Islam as a way of practicing patience and good manners rather than creating excessive hardship or safety challenge, patients with very high and high risk of diabetic complications as described by the American Diabetic Association are advised not to fast, whereas patients with low and medium risk are expected to fast.[@b8-ppa-10-1709]--[@b10-ppa-10-1709]

Although religiously exempted, the vast majority of Saudi patients with type 2 diabetes (T2D) insist on fasting during Ramadan.[@b5-ppa-10-1709],[@b11-ppa-10-1709] As the daily fasting hours varies by season and geographic locations, the current Ramadan seasons come during summer months with hot weather and long fasting duration, reaching \~15 hours in most Islamic countries, including Saudi Arabia.[@b12-ppa-10-1709] This probably increases the risk of acute diabetic complications. Lack of patient education prior to Ramadan may contribute to suboptimal practices.[@b13-ppa-10-1709] Many of the diabetic patients who fast in this month without any medical guidance often end up developing acute complications.[@b14-ppa-10-1709]

Current guidelines recommend that diabetic patients should have counseling and education about the need to modify medication dose and timing, dietary habits, physical activity, and self-monitoring of blood sugar to reduce the risk of acute diabetic complications.[@b3-ppa-10-1709],[@b9-ppa-10-1709]

Two studies from Pakistan and the UK have shown the Ramadan education program to be successful in protecting against serious acute diabetic complications.[@b15-ppa-10-1709],[@b16-ppa-10-1709] Moreover, the current management guidelines stress on individualized approach of diabetic care during Ramadan.[@b3-ppa-10-1709],[@b9-ppa-10-1709] Therefore, as diabetes management in Ramadan needs special considerations, there are several guidelines addressing its management in Ramadan, including International Diabetes Federation, the Diabetes and Ramadan International Alliance practical guidelines,[@b17-ppa-10-1709] and others.[@b9-ppa-10-1709],[@b18-ppa-10-1709]

Despite the high prevalence of diabetes and difficult environmental conditions,[@b6-ppa-10-1709],[@b7-ppa-10-1709],[@b12-ppa-10-1709] there is a lack of studies that have examined the impact of such focused education program among Saudi patients with T2D. Therefore, the aim of this study is to examine the impact of Ramadan focused education program (RFEP) on hypoglycemia, glycemic control, and other clinical and metabolic parameters among a group of T2D patients receiving care at a primary care center in Riyadh, Saudi Arabia.

Methods
=======

Setting
-------

The study was conducted in Al-Wazarat Healthcare Center, a big family medicine center in Riyadh, Saudi Arabia. The total monthly number of diabetic patients visiting the center is \~13,000. Diabetic patients are served by family medicine clinics (six morning and five afternoon clinics) run by family physicians, a clinical pharmacy clinic (covers ten sessions per week) run by a clinical pharmacist, and other clinics run by diabetic educator, health educator, dietitian, and social worker. The current data are collected from the clinical pharmacy clinic.

Population
----------

The study included patients with T2D who were receiving care at the Al-Wazarat Healthcare Center at the time of the study. Exclusion criteria included serious comorbidities such as unstable angina or severe hepatic/renal disease, elderly patients with alertness problems, newly diagnosed T2D (\<3 months), recent hospitalization, hypoglycemia during the past month or unawareness of hypoglycemia, and partially or completely nonfasting during the month of Ramadan.

Design
------

A nonrandomized interventional controlled design was used between June 2013 and February 2014. The study was done in three phases: first phase (2--3 weeks before Ramadan, enrollment), second phase (the third week of Ramadan), and third phase (4 weeks after Ramadan, HbA1c measured 12 weeks after Ramadan). The study was approved by the research committee in Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Intervention
------------

The intervention group received the RFEP before and after Ramadan while the control group received standard diabetic care. The standard care was provided as per the American Diabetes Association standard of medical care and guidelines.[@b19-ppa-10-1709]--[@b21-ppa-10-1709] The RFEP was carried out by the clinical pharmacist, primary care physician, and dietician through individual and/or group sessions (as appropriate) for \~40--60 minutes. The educational intervention included audiovisual material and written brochures focused on diabetes self-care, including signs and symptoms of hyper- and hypoglycemia, self-monitoring of blood glucose, physical activity, care of diabetic foot, and management of acute complications. Patients were encouraged to frequently monitor for glycemia and immediately end their fast in case of hypoglycemia (blood glucose \<60 mg/dL). Patients were also advised to adjust the dosage and timing of oral hypoglycemic agents and insulin according to the 2010 recommendations for management of diabetes during Ramadan.[@b9-ppa-10-1709] For example, two-third of biguanide or metformin or insulin dose should be given at sunset meal, while a one-third of the dose should be given before the predawn meal. Additionally, patients received individualized diet advice (by dietician), including diet adjustment, preferred and nonpreferred food items, preferred way for breaking fasting, and best timing of second meal. The post-Ramadan education was focused on readjusting antidiabetic medications to prediabetic levels according to blood glucose level and clinical parameters.

Outcome
-------

The main study outcome was postintervention change of HbA1c and hypoglycemia. Glycemic control was defined as HbA1c \<7%. The risk of hypoglycemia was assessed using hypoglycemia score. Other outcomes included postintervention change of body weight, blood pressure, and lipid profile. The outcomes were measured before, during, and after Ramadan.

Sampling and recruitment
------------------------

Patients were recruited from daily follow-up in the clinical pharmacy clinic using the convenience sampling technique. Patients who meet the eligibility criteria were informed about the study during their regular care before Ramadan. Patients who were able to provide an informed consent were included in the study. The study controls were recruited consecutively after completing the recruitment of the patients in the intervention.

Sample size calculation
-----------------------

A number of studies showed that the patients who received Ramadan-focused education had \~60% reduced risk of hypoglycemic events compared to the control group.[@b15-ppa-10-1709],[@b16-ppa-10-1709] Therefore, to be able to detect 60% risk reduction of hypoglycemic events, we estimated that a total of 266 participants are required, assuming 20% prevalence of hypoglycemic events in the control group, 80% power, and 95% two-sided confidence level. Additionally, to detect an absolute difference (increase or reduction) in HbA1c by 1%, we will need 198 patients (99 in each group) assuming 9% HbA1c in the control group, standard deviation of 2.5%, 80% power, and 95% two-sided confidence level.

Data collection tools
---------------------

Data were collected through a structured questionnaire, which included sociodemographic information, duration of diabetes, clinical and metabolic parameters, such as body mass index (BMI), systolic and diastolic blood pressure, lipid profile, HbA1c, current antidiabetic medications and hypoglycemia questionnaire introduced by the Hypoglycemic Health Association of Australia.[@b22-ppa-10-1709] Face and content validity of the questionnaire was done by three experts in the field of diabetes management. Since the questionnaire needed to be administered in Arabic, bidirectional translation of the questionnaire, including the hypoglycemia part, was done. Additionally, pilot study was done on 15 participants and the feedback was used to improve the understanding of the questionnaire. Reliability of the hypoglycemia questionnaire was found to be satisfactory (Cronbach's alpha of 0.873).

Statistical methods
-------------------

Patients' demographic, clinical, and biomedical information were presented as mean and standard deviation for continuous variables, and frequency and percentages for categorical variables. To examine the significance of the changes in glycemic control and other study outcomes across the three phases of the study, repeated measures analysis of variance was run for continuous variables. For the repeated measures analysis of variance, the *P*-value of Wilks' Lambda is reported and when statistically significant, a post hoc analysis was performed using Bonferroni test to adjust for multiple comparisons. For categorical variables, Mantel--Haenszel chi-square was used. To examine the difference in study outcomes between the intervention and control groups during the study phases, independent *t*-test (or its equivalent Mann--Whitney *U*-test) was used for continuous variables and chi-square for categorical variables. The percentage change of the study outcomes was defined as the amount of post-/preintervention change in relation to the preintervention level. The difference in the percentage change of the study outcomes between the two groups were examined using *t*-test, which was used for continuous variables, and chi-square for categorical variables. To detect group difference in post-Ramadan reduction in HbA1c and hypoglycemia score after adjusting for several demographic characteristics, a multivariate linear regression analysis was run. All *P*-values were two-tailed. *P*-value \<0.05 was considered as significant. SPSS software (release 20.0, IBM Corporation, Armonk, NY, USA) was used for all statistical analyses. Sample size calculation was done using OpenEpi software (version 2.2, Copyright© 2003, 2007 Andrew G. Dean and Kevin M. Sullivan, Atlanta, GA, USA).

Results
=======

A total of 262 patients with T2D were included in the study; 140 patients in the intervention group and 122 patients in the control group. The demographic and clinical characteristics of both groups are described in [Table 1](#t1-ppa-10-1709){ref-type="table"}. The mean age was similar in both groups (55.12±12.76 years in the intervention group vs 56.06±11.08 years in the control). The majority of patients were females in both groups (60.0% vs 66.4%, respectively). The intervention group and the control group were similar in terms of BMI (32.93±6.70 vs 32.71±7.14, respectively) similar blood pressure (68.6% vs 71.3%, respectively, had similar blood pressure). However, a higher proportion of patients in the intervention group were living outside Riyadh compared with the control group (14.3% vs 6.6%, respectively *P*=0.043). Also, a higher proportion of the intervention were unemployed compared with the control group (46.4% vs 12.3%, respectively *P*\<0.001).

The average duration of diabetes was \~13 years in both groups ([Table 1](#t1-ppa-10-1709){ref-type="table"}). The majority of patients in both groups were using insulin (95.7% vs 91.0%, respectively) and oral antidiabetic medications (84.3% vs 82.8%, respectively). Patients in the intervention group had more mixed types of insulin (1.71±0.57 vs 1.14±0.55, *P*\<0.001) but similar number of oral antidiabetic medications. Patients in both groups had similar HbA1c (9.79±1.89 vs 10.04±1.47, respectively) and hypoglycemia score (14.21±8.50 vs 14.01±5.10). However, patients in the intervention group had no acute complications compared with 4.9% in the control group (*P*=0.008). Both groups had similar lipid profile, including low-density lipoprotein (LDL), high-density lipoprotein, and total cholesterol and triglycerides.

[Table 2](#t2-ppa-10-1709){ref-type="table"} summarizes the impact of RFEP on physical, physiological, and biomedical parameters by comparing the three phases of the study. Both LDL and total cholesterol significantly decreased in the intervention group during Ramadan and became significantly lower than the control group. However, such changes were partially lost after Ramadan. While both intervention and control groups continued to show improvement of high-density lipoprotein cholesterol during and after Ramadan, there was no statistically significant difference between the intervention and the control group. While body weight and BMI did not significantly change during the study, the slight baseline difference between groups (being lower in the control group) widen after Ramadan to become significant. On the other hand, the number of insulin types remained consistently higher in the intervention group compared with control group without any significant change during the study. Additionally, there were no changes in the blood pressure during the study.

[Table 3](#t3-ppa-10-1709){ref-type="table"} shows the impact of RFEP on glycemic control and hypoglycemia score. HbA1c levels were 9.79, 8.26, and 8.52 before, during, and after Ramadan in the intervention group, respectively (*P*\<0.001) and 10.04, 9.54, and 9.59 in the control group, respectively (*P*\<0.001). Both groups were significantly different at the end of the study (*P*\<0.001). Those who had targeted glycemic control (\<7) significantly increased during the study in the intervention (*P*=0.002) but not the control (*P*=0.711), and the significant difference between both groups before Ramadan (8.6% vs 1.6%, *P*=0.013) significantly widen after Ramadan (19.3% vs 3.3%, *P*\<0.001). The mean of hypoglycemia scores before, during, and after Ramadan was 14.21, 6.36, and 5.44 in the intervention group, respectively, (*P*\<0.001) and 14.01, 13.46, and 9.27 in the control group, respectively (*P*\<0.001). Both groups were significantly different at the end of the study (*P*\<0.001).

As shown in [Figure 1](#f1-ppa-10-1709){ref-type="fig"}, the post-Ramadan reduction of both HbA1c levels and hypoglycemia score was significantly higher in intervention compared with control groups (−13.0% vs −4.5%, *P*=0.004 for HbA1c levels and −61.7% vs −33.8%, *P*\<0.001 for hypoglycemia score). Similarly, post-Ramadan achievement of the target HbA1c (\<7) and hypoglycemia score (\<8) were more in intervention compared with control groups. In [Table 4](#t4-ppa-10-1709){ref-type="table"}, multivariate linear regression analysis adjusted for age, sex, BMI, education, residence, and job showed 7.2% more post-Ramadan reduction in HbA1c (*P*=0.004) and 3.16 points more post-Ramadan reduction in hypoglycemia score (*P*\<0.001) in the intervention group compared with the control group.

Discussion
==========

General education programs that focus on self-management of diabetes care have been shown in several studies to have a beneficial effect on the glycemic control and other management outcomes in patients with T2D, both in the short- and probably the long-term as well.[@b23-ppa-10-1709],[@b24-ppa-10-1709] Moreover, education of diabetes management is more critical for patients with T2D who insist to fast during Ramadan. However, some studies from other countries have shown that education could increase the awareness of adverse effects and proper management of diabetes.[@b25-ppa-10-1709],[@b26-ppa-10-1709] Fasting during Ramadan is a great challenge due to sudden alteration in daily dietary and physical activity, which may represent a considerable risk in some diabetic patients.[@b3-ppa-10-1709]--[@b5-ppa-10-1709] For example, studies done in multiple countries showed that fasting may be responsible for up to sevenfold higher risk of hypoglycemia, especially among those on insulin and those who are physically active.[@b11-ppa-10-1709],[@b16-ppa-10-1709]

The educational intervention received by the study patients was a multifaceted program run by different specialties, tailored for individual needs, and covering all standard recommendations for better diabetic management during Ramadan, including frequent glucose monitoring, medication and dose adjustments, proper meal planning, proper maintaining of physical activity, and situations that require breaking the fast.[@b3-ppa-10-1709],[@b9-ppa-10-1709]

The current finding showed a beneficial impact of RFEP on the risk of hypoglycemia. Almost all the previous studies that examined the impact of similar education programs showed protective effect on the risk of hypoglycemia.[@b15-ppa-10-1709],[@b16-ppa-10-1709],[@b27-ppa-10-1709] For example, pre-Ramadan-focused education among UK Muslim patients with T2D was associated with approximately 60% reduction in hypoglycemia during Ramadan compared with fourfold increase in hypoglycemia among controls.[@b16-ppa-10-1709] Similarly, a prospective study in Pakistan showed that the majority of outpatients who attended two educational sessions on drug dosage and timing alteration, glucose monitoring, and dietary and lifestyle modifications did not have any serious acute diabetic complications during Ramadan.[@b15-ppa-10-1709] Additionally, hypoglycemia was less frequently seen during Ramadan among fasting diabetic patients in UAE who received pre-Ramadan targeted education compared with their control counterparts (27% vs 6%). The education-directed modification in lifestyle and medication (type, dose, and timing) may have resulted in minimizing the risk of acute complications in our patients.[@b25-ppa-10-1709] Although to a much lesser extent, reducing the risk of hypoglycemia in the current study was also shown among the control group. This could be explained by the fact that there is generally good standard diabetes management in the clinic.

The current study showed a beneficial impact of RFEP on glycemic control and hypoglycemia. However, improvement in hypoglycemia was much more than the improvement in the glycemic control. This could be explained by the fact that considerable changes in HbA1c needs longer duration of sustained blood glucose control, which is beyond the 1-month Ramadan fasting. Pre-Ramadan education was associated with generally modest positive impact on glycemic control in the majority of previous studies[@b15-ppa-10-1709],[@b16-ppa-10-1709],[@b27-ppa-10-1709] but not all of them.[@b28-ppa-10-1709] Interestingly, unlike the risk of hypoglycemia, the impact of Ramadan fasting on biochemical parameters is probably mild. A couple of reviews showed that the majority of studies reported no change in HbA1c in patients with T2D.[@b29-ppa-10-1709],[@b30-ppa-10-1709] On the other hand, smaller number of studies showed decrease or increase of HbA1c during Ramadan fasting.[@b29-ppa-10-1709],[@b30-ppa-10-1709]

The current study showed a mild positive impact of RFEP on lipid profile that was rapidly lost after Ramadan. Additionally, there was no beneficial impact on blood pressure or body weight. Similar to our results, pre-Ramadan targeted diabetes education in UAE was associated with insignificant changes in total cholesterol, triglycerides, and body weight.[@b27-ppa-10-1709] Additionally, pre-Ramadan-focused education among UK Muslim patients with T2D was associated with only 0.7 kg weight loss in the intervention and 0.6 kg weight gain in the control group after Ramadan.[@b16-ppa-10-1709] Unlike acute complications and glycemic control, body weight, blood pressure, and lipid profile were rarely used as an outcome for pre-Ramadan education programs in previous studies. On the other hand, several studies showed that Ramadan fasting has minimal impact on lipid profile of diabetic patients, with some studies showing decrease, increase, or no change of blood cholesterol.[@b12-ppa-10-1709],[@b29-ppa-10-1709],[@b30-ppa-10-1709] Additionally, it was shown that Ramadan fasting is associated with no weight change in 50%--60% but weight gain in 20%--25% of individuals.[@b31-ppa-10-1709]

Strengths and limitations
=========================

The current study had strengths; it used a controlled design for measuring multiple outcomes including acute complications and biomedical parameters, measured during three phases (pre-, during, post-Ramadan). Nevertheless, we acknowledge some limitations. The nonrandomized approach is a limitation of this study, as the subjects were first enrolled into the intervention arm and then the control arm subjects were enrolled. However, this approach is not uncommon in the literature.[@b32-ppa-10-1709],[@b33-ppa-10-1709] According to Falk and Hagesund, this approach is considered appropriate if the purpose of study design was to mimic the clinical routine in the primary care setting, and to compare the intervention with the ordinary care without the opportunity to have this intervention.[@b32-ppa-10-1709]

Moreover, regarding the comparability between the two arms in terms of the baseline characteristics, there were no statistically significant differences between the intervention and the control group for most demographic characteristics and clinical parameters. However, there were few differences, particularly in terms of residency and job status. There was a higher proportion of patients in the intervention group who were living outside Riyadh compared with the control group. Moreover, patients in the intervention group had more mixed types of insulin and hence had more tendency to hypoglycemia. However, the program was effective in reducing the risk of hypoglycemia despite the challenge that the intervention group might be more difficult to manage in this particular aspect. However, we believe the impact of these differences is minimal, as evidenced by maintaining the group difference in the outcome in multivariate analysis. Therefore, overall, we believe that study results are robust. However, these limitations should be taken into consideration when interpreting the results and conclusions of the study.

Conclusion
==========

Ramadan educational program had a positive impact, with reduction of hypoglycemic risk, HbA1c, and LDL cholesterol. Therefore, it could be recommended for patients with increased risk of hypoglycemia during Ramadan fasting.
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###### 

Baseline demographic and clinical characteristics in the intervention and control groups

  Variable                                                            Intervention (n=140)   Control (n=122)   Test value    *P*-value
  ------------------------------------------------------------------- ---------------------- ----------------- ------------- -----------------------------------------------------
  **Age (years)**                                                                                                            
  Mean ± SD                                                           55.12±12.76            56.06±11.08       *t*=0.630     0.530
   \<50                                                               42 (30.0)              30 (24.6)         χ^2^=4.675    0.097
   50--59                                                             52 (37.1)              36 (29.5)                       
   ≥60                                                                46 (32.9)              56 (45.9)                       
  **Sex**                                                                                                                    
  Male                                                                56 (40.0)              41 (33.6)         χ^2^=1.143    0.285
  Female                                                              84 (60.0)              81 (66.4)                       
  **Residence**                                                                                                              
  Riyadh                                                              120 (85.7)             114 (93.4)        χ^2^=4.079    0.043[\*](#tfn3-ppa-10-1709){ref-type="table-fn"}
  Outside Riyadh                                                      20 (14.3)              8 (6.6)                         
  **Job status**                                                                                                             
  Unemployed                                                          65 (46.4)              15 (12.3)         χ^2^=35.809   \<0.001[\*](#tfn3-ppa-10-1709){ref-type="table-fn"}
  Working                                                             75 (53.6)              107 (87.7)                      
  **Body weight**                                                     84.16±18.04            81.01±17.71       *t*=1.395     0.164
  **BMI**                                                                                                                    
  Mean ± SD                                                           32.93±6.70             32.71±7.14        *t*=0.250     0.803
   Normal (\<25)                                                      15 (10.7)              11 (9.0)          χ^2^=1.971    0.578
   Overweight (25--29)                                                32 (22.9)              37 (30.3)                       
   Obese (30--34)                                                     40 (28.6)              31 (25.4)                       
   Morbid obese (≥35)                                                 50 (35.7)              40 (32.8)                       
  **BP**                                                                                                                     
  Hypertension (\>130/80)                                             96 (68.6)              87 (71.3)         χ^2^=0.232    0.630
   Systolic BP                                                        130.14±13.85           130.12±15.40      *t*=0.011     0.991
   Diastolic BP                                                       73.34±8.94             72.98±8.88        *t*=0.319     0.750
  **Diabetes and its management**                                                                                            
  Duration (years)                                                    12.95±8.39             12.86±7.61        *U*=0.092     0.927
  On oral medications                                                 118 (84.3)             101 (82.8)        χ^2^=0.107    0.744
  On insulin                                                          134 (95.7)             111 (91.0)        χ^2^=2.404    0.121
  Number of oral medications                                          0.97±0.55              0.88±0.47         *U*=1.479     0.140
  Number of insulin types                                             1.71±0.57              1.14±0.55         *U*=8.307     \<0.001[\*](#tfn3-ppa-10-1709){ref-type="table-fn"}
  Hypoglycemia score                                                  14.21±8.50             14.01±5.10        *t*=0.234     0.815
  Acute complications[\*\*](#tfn2-ppa-10-1709){ref-type="table-fn"}   0 (0.0)                6 (4.9)           χ^2^=7.047    0.008[\*](#tfn3-ppa-10-1709){ref-type="table-fn"}
  HbA1c                                                               9.79±1.89              10.04±1.47        *t*=−1.196    0.233
  **Lipid profile**                                                                                                          
  LDL cholesterol                                                     2.41±0.91              2.53±0.86         *t*=−1.041    0.299
  HDL cholesterol                                                     1.14±0.30              1.14±0.30         *t*=−0.075    0.940
  Total cholesterol                                                   4.35±1.13              4.42±1.27         *t*=−0.475    0.635
  Triglycerides                                                       1.62±0.79              1.86±1.48         *t*=−1.665    0.097

**Notes:** χ^2^, chi-square test; *t*, Student *t*-test; *U*, Mann--Whitney *U*-test.

Complications that occurred in the previous Ramadan.

Statistically significant difference at *P*\<0.05.

**Abbreviations:** BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

###### 

Impact of Ramadan focused education program on clinical characteristics during the study phases in the intervention and control groups

  Variable                         Pre-Ramadan        During Ramadan     Post-Ramadan       Phase difference
  -------------------------------- ------------------ ------------------ ------------------ ------------------
  **Body weight (kg)**                                                                      
  Intervention                     84.16±18.04        85.85±17.37        85.38±17.09        0.063
  Control                          81.01±17.71        81.30±17.48        80.21±17.13        0.434
   Group difference                *P*=0.164          *P*=0.038^\*^      *P*=0.017^\*^      
  **BMI**                                                                                   
  Intervention                     32.93±6.70         33.74±6.46         33.49±6.52         0.296
  Control                          32.71±7.14         32.45^\#^±7.00     31.50^\#^±6.63     0.013
   Group difference                *P*=0.803          *P*=0.126          *P*=0.016^\*^      
  **Systolic BP**                                                                           
  Intervention                     130.14±13.85       130.87±15.57       130.52±15.71       0.876
  Control                          130.12±15.40       131.20±15.24       130.21±14.25       0.714
   Group difference                *P*=0.991          *P*=0.865          *P*=0.869          
  **Diastolic BP**                                                                          
  Intervention                     73.34±8.94         72.29±10.31        72.39±9.77         0.558
  Control                          72.98±8.88         73.30±9.30         72.98±8.78         0.925
   Group difference                *P*=0.750          *P*=0.408          *P*=0.605          
  **LDL cholesterol**                                                                       
  Intervention                     2.41^\#^±0.91      2.12^\#,\$^±0.68   2.28^\$^±0.73      \<0.001^\*^
  Control                          2.53±0.86          2.46±0.89          2.60±0.98          0.109
   Group difference                *P*=0.299          *P*=0.001^\*^      *P*=0.003^\*^      
  **HDL cholesterol**                                                                       
  Intervention                     1.14^\#,\$^±0.30   1.19^\#^±0.31      1.23^\$^±0.38      0.001^\*^
  Control                          1.14^\#,\$^±0.30   1.24^\#,^\^±0.33   1.29^\$,\^^±0.34   \<0.001^\*^
   Group difference                *P*=0.940          *P*=0.211          *P*=0.214          
  **Total cholesterol**                                                                     
  Intervention                     4.35^\#,\$^±1.13   4.00^\#^±0.91      4.08^\$^±1.06      \<0.001^\*^
  Control                          4.42±1.27          4.26±1.18          4.32±1.23          0.319
   Group difference                *P*=0.635          *P*=0.047^\*^      *P*=0.088          
  **Triglycerides**                                                                         
  Intervention                     1.62^\#^±0.79      1.49^\#^±0.72      1.53±0.93          0.028^\*^
  Control                          1.86±1.48          1.68±0.87          1.75±0.90          0.260
   Group difference                *P*=0.097          *P*=0.054          *P*=0.053          
  **Number of oral medications**                                                            
  Intervention                     0.97±0.55          0.99±0.57          0.98±0.57          0.874
  Control                          0.88±0.47          0.84±0.46          0.89±0.53          0.438
   Group difference                *P*=0.140          *P*=0.023^\*^      *P*=0.212          
  **Number of insulin types**                                                               
  Intervention                     1.71±0.57          1.64±0.63          1.64±0.61          0.331
  Control                          1.14±0.55          1.07±0.53          1.11±0.52          0.063
   Group difference                *P*\<0.001^\*^     *P*\<0.001^\*^     *P*\<0.001^\*^     

**Note:** Symbols (\#, \$, \^) indicate the statistical differences between the phases (^\*^*P*\<0.05).

**Abbreviations:** BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

###### 

Impact of Ramadan focused education program on glycemic control and hypoglycemia score during the study phases in the intervention and control groups

  Variable                               Pre-Ramadan         During Ramadan   Post-Ramadan       Phase difference
  -------------------------------------- ------------------- ---------------- ------------------ ------------------
  **HbA1c**                                                                                      
  Intervention                           9.79^\#,\$^±1.89    8.26^\#^±1.54    8.52^\$^±1.61      \<0.001^\*^
  Control                                10.04^\#,\$^±1.47   9.54^\#^±1.38    9.59^\$^±1.79      \<0.001^\*^
   Group difference (repeated measure)   *P*=0.233           *P*≤0.001^\*^    *P*≤0.001^\*^      
  **HbA1c** \<**7**                                                                              
  Intervention                           12 (8.6)            34 (24.3)        27 (19.3)          0.002^\*^
  Control                                2 (1.6)             3 (2.5)          4 (3.3)            0.711
   Group difference                      *P*=0.013^\*^       *P*≤0.001^\*^    *P*≤0.001^\*^      
  **Hypoglycemia score**                                                                         
  Intervention                           14.21^\#,\$^±8.50   6.36^\#^±6.17    5.44^\$^±5.55      \<0.001^\*^
  Control                                14.01^\#^±5.10      13.46^\$^±5.30   9.27^\#,\$^±4.65   \<0.001^\*^
   Group difference                      *P*=0.815           *P*≤0.001^\*^    *P*≤0.001^\*^      
  **Hypoglycemia score** \<**8**                                                                 
  Intervention                           35 (25.0)           95 (67.9)        103 (73.6)         \<0.001^\*^
  Control                                10 (8.2)            15 (12.3)        41 (33.6)          \<0.001^\*^
   Group difference                      *P*\<0.001^\*^      *P*\<0.001^\*^   *P*\<0.001^\*^     

**Note:** Symbols (\#, \$, \^) indicate the statistical differences between the phases (^\*^*P*\<0.05).

**Abbreviation:** SD, standard deviation.

###### 

Multiple linear regression model to predict HbA1c and hypoglycemia score by the study groups[a](#tfn10-ppa-10-1709){ref-type="table-fn"}

  Variable                        Unstandardized coefficients   Standardized coefficients   *t*-test   *P*-value   95% confidence interval for B            
  ------------------------------- ----------------------------- --------------------------- ---------- ----------- ------------------------------- -------- --------
  **HbA1c (%)**                                                                                                                                             
  Constant                        −17.75                        3.86                                   −4.602      \<0.001                         −25.35   −10.16
  Intervention vs control group   −7.20                         2.49                        −0.18      −2.888      0.004                           −12.11   −2.29
  **Hypoglycemia (points)**                                                                                                                                 
  Constant                        −12.15                        1.74                                   6.977       \<0.001                         8.73     −15.57
  Intervention vs control group   −3.16                         0.50                        −0.22      6.351       \<0.001                         2.19     −4.14
  Age                             0.08                          0.02                        0.14       −3.700      \<0.001                         0.13     0.04
  Education                       0.81                          0.20                        0.16       −4.114      \<0.001                         1.20     0.42

**Notes:** *r*-square =0.03.

Adjusted for age, sex, education, residence, job, BMI.

**Abbreviation:** BMI, body mass index.
